XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:    
Total revenue $ 72,049 $ 77,262
Operating expenses:    
Research and development 18,711 24,357
Sales and marketing 19,830 23,231
General and administrative 26,911 28,032
Total operating expenses 91,386 101,586
Loss from operations (19,337) (24,324)
Other income:    
Interest income, net 2,885 2,666
Change in estimated fair value of common stock warrant liability 0 7
Other expense, net (290) (1,974)
Total other income 2,595 699
Loss before income taxes (16,742) (23,625)
Income tax benefit (expense) 83 (124)
Net loss $ (16,659) $ (23,749)
Net loss per share    
Basic (in dollars per share) $ (0.32) $ (0.44)
Diluted (in dollars per share) $ (0.32) $ (0.44)
Weighted-average shares used to compute net loss per share:    
Basic (in shares) 51,692,358 53,643,216
Diluted (in shares) 51,692,358 53,643,216
Testing services revenue    
Revenue:    
Total revenue $ 53,837 $ 61,784
Operating expenses:    
Cost of testing services, product, digital, and other 13,632 15,296
Product revenue    
Revenue:    
Total revenue 8,594 6,861
Operating expenses:    
Cost of testing services, product, digital, and other 5,344 4,066
Patient and digital solutions revenue    
Revenue:    
Total revenue 9,618 8,617
Operating expenses:    
Cost of testing services, product, digital, and other $ 6,958 $ 6,604